BELITE BIO, INC
BELITE BIO, INC (BLTE): 1 pipeline candidate · 1 upcoming catalyst · ~32 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
32.1 months
D/E 0.01 · 0% dilution
Lead: Phase 3
1 candidate
1 upcoming, next in ~593d
0 buys · 112 sells (180d)
A transparent, data-derived signal for BELITE BIO, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.9B
Cash
$352.9M
Quarterly Burn
$37.0M
Runway
32.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| tinlarebant | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
71
Total value held
$549.2M
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 715,332 | $114.1M |
| millennium management llc | 570,088 | $90.9M |
| eventide asset management, llc | 357,650 | $57.0M |
| deerfield management company, l.p. | 304,013 | $48.5M |
| perceptive advisors llc | 303,958 | $48.5M |
| morgan stanley | 201,409 | $32.1M |
| patient square capital lp | 116,684 | $18.6M |
| goldman sachs group inc | 105,509 | $16.8M |
| mpm bioimpact llc | 88,045 | $14.0M |
| affinity asset advisors, llc | 65,000 | $10.4M |
Showing top 10 of 71 institutional holders of BELITE BIO, INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BELITE BIO, INC's pipeline?
BELITE BIO, INC (BLTE) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is BELITE BIO, INC's lead drug candidate?
BELITE BIO, INC's most advanced tracked candidate is tinlarebant (Phase 3) for STGD1.
What is BELITE BIO, INC's next catalyst?
BELITE BIO, INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerabi" — expected February 1, 2028.
What is BELITE BIO, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BELITE BIO, INC has approximately 32.1 months of cash runway.
What is BELITE BIO, INC's market capitalization?
BELITE BIO, INC's market capitalization is approximately $5.9B.
Get the full picture on BELITE BIO, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.